10-K: Cidara Therapeutics Reports Fiscal Year 2024 Results, Highlights CD388 Progress

Cidara Therapeutics focuses on CD388 development after divesting rezafungin, reporting a net loss of $169.8 million for fiscal year 2024.

Summary

• Cidara Therapeutics is now focused on developing drug-Fc conjugate (DFC) immunotherapies using its Cloudbreak platform.
• The company's lead asset is CD388, a DFC for influenza prophylaxis, for which they reacquired rights from Janssen in April 2024.
• A private placement in April 2024 generated $240.0 million, with $85.0 million used for the Janssen license and the remainder for CD388 development.
• Cidara divested rezafungin to Napp Pharmaceutical Group in April 2024 to concentrate on the Cloudbreak platform.
• The Cloudbreak platform is designed to create DFCs that target diseases and engage the immune system.
• The company initiated the CD388 Phase 2b NAVIGATE study in September 2024 and completed enrollment of 5,000 subjects in December 2024, with topline data expected in Q3 2025.
• Cidara's lead oncology DFC candidate, CBO421, received IND clearance in July 2024, but clinical trials are not planned at this time.
• The company reported a net loss of $169.8 million for the year ended December 31, 2024, compared to a net loss of $22.9 million in 2023.
• As of December 31, 2024, Cidara had cash, cash equivalents, and restricted cash of $196.2 million.
• The company anticipates needing additional funding to advance CD388 beyond Phase 2b and to progress CBO421 and other Cloudbreak programs.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive developments such as the reacquisition of CD388 and the completion of enrollment in the Phase 2b trial, the significant net loss and the need for additional funding create uncertainty.

Positives

• Cidara reacquired rights to CD388, a promising influenza prophylaxis candidate.
• The company secured significant funding through private placements to support CD388 development.
• The CD388 Phase 2b NAVIGATE study is fully enrolled, with topline data expected in Q3 2025.
• Cidara's Cloudbreak platform has potential for developing novel immunotherapies.
• CBO421 received IND clearance, indicating progress in the oncology program.
• The company divested rezafungin to focus resources on its core Cloudbreak platform.

Negatives

• Cidara reported a substantial net loss of $169.8 million for fiscal year 2024.
• The company is dependent on raising additional capital to continue its development programs.
• There are no current plans to initiate clinical trials for the oncology program.
• The company implemented a reduction in workforce of 30% in September 2024.

Risks

• The company's success is heavily dependent on the success of CD388, which is still in clinical development.
• Clinical trials may be delayed, terminated, or fail to demonstrate safety and efficacy.
• The company faces substantial competition in the biopharmaceutical industry.
• The company may not be successful in identifying and developing potential product candidates through its Cloudbreak platform.
• The company relies on third parties for clinical trials and manufacturing, which could lead to delays or other issues.
• The company may not be able to obtain required regulatory approvals.
• The company may be subject to product liability lawsuits.
• The company may be subject to unfavorable pricing regulations or healthcare reform initiatives.
• The company may be unable to generate revenues from partnerships, government funding, or other sources.
• The price of the company's stock may be volatile.

Future Outlook

Cidara expects to continue to incur significant expenses and increasing operating losses for the foreseeable future. Topline data from the CD388 Phase 2b NAVIGATE study is expected in the third quarter of 2025. The company may consider a potential early analysis of efficacy data from the ongoing CD388 Phase 2b NAVIGATE study in the first half of 2025. If an analysis of the CD388 Phase 2b NAVIGATE study is completed in the first half of 2025, such results will be disclosed and the company may consider initiating a Phase 3 study during the 2025-26 Northern Hemisphere influenza season.

Management Comments

• We believe the reacquisition of CD388 is transformational for Cidara and potentially for those who could benefit from a long-acting, universal preventative against known forms of influenza.

Industry Context

The biopharmaceutical industry is characterized by intense competition to develop new technologies and proprietary therapies. Cidara faces competition from larger pharmaceutical and biotechnology companies, as well as academic institutions and research organizations. The company expects CD388 to compete with approved and investigational agents for the treatment or prevention of viral influenza infections, including influenza vaccines, monoclonal antibodies targeting hemagglutinin, and small molecule neuraminidase inhibitors and endonuclease inhibitors.

Comparison to Industry Standards

• Cidara's CBO421 would compete against approved anticancer therapeutics as well as investigational CD73-targeting small molecule drugs, including quemliclustat being developed by Arcus Biosciences, Inc. and monoclonal antibodies, including oleclumab being developed by AstraZeneca PLC.
• Many of Cidara's competitors have substantially greater financial, technical and human resources than Cidara does and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and commercializing those treatments.

Management Changes

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees were affected by the reduction in workforce.
• Patients may benefit from the development of new therapies, particularly CD388 for influenza.
• Suppliers and manufacturers may be impacted by changes in the company's development programs.

Next Steps

• The company expects topline data from the CD388 Phase 2b NAVIGATE study in the third quarter of 2025.
• The company may consider a potential early analysis of efficacy data from the ongoing CD388 Phase 2b NAVIGATE study in the first half of 2025.
• If an analysis of the CD388 Phase 2b NAVIGATE study is completed in the first half of 2025, such results will be disclosed and the company may consider initiating a Phase 3 study during the 2025-26 Northern Hemisphere influenza season.
• The company will continue business development discussions for its oncology DFC programs, including CBO421.

Key Dates

Keywords

CD388, Cloudbreak, Rezafungin, CBO421, Influenza, Oncology, Clinical Trials, Janssen, Private Placement, DFC, Immunotherapy, Biotechnology